ASH 2014: AbbVie's venetoclax gets responses in pre-treated AML
This article was originally published in Scrip
Acute myelogenous leukemia (AML) patients enrolled in AbbVie's ongoing Phase II clinical trial for venetoclax (ABT-199) achieved 19% overall response rate, but even with fewer than one-fifth of patients responding, the trial's lead investigator said the results were "promising" in this heavily pre-treated population.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.